Prudential Financial
KROS icon

Prudential Financial’s Keros Therapeutics KROS Stock Holding History

Prudential Financial’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-11,172
Closed -$477K – 2660
2023
Q1 		$477K Sell
11,172
-200
-2% -$10.1K ﹤0.01% 2086
2022
Q4 		$546K Buy
11,372
+135
+1% +$6.31K ﹤0.01% 1989
2022
Q3 		$423K Buy
+11,237
New +$389K ﹤0.01% 2141

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Prudential Financial's KROS Position: Q2 2023 in Review

Prudential Financial sold out of Keros Therapeutics (KROS) in Q2 2023, closing a stake of 11,172 shares — an estimated $477K sold.

Prudential Financial first reported a position in KROS in Q3 2022 and held it in 3 quarters. The position peaked at $546K in Q4 2022. 123 funds tracked by Wall St. Rank hold KROS as of Q2 2023.

  • Prudential Financial reported no remaining Keros Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Prudential Financial sold 11,172 Keros Therapeutics shares in Q2 2023, an estimated $477K.
  • Prudential Financial first reported a position in Keros Therapeutics in Q3 2022 and held it in 3 quarters.
  • Prudential Financial's Keros Therapeutics position peaked at $546K in Q4 2022.
  • 123 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2023.

Based on Prudential Financial's 13F filing for Q2 2023, filed 11 Aug 2023.